Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
Posted in biotech/medical